| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5693790 | European Urology | 2017 | 7 Pages |
Abstract
We compared radiotherapy utilization and survival for prostate cancer (PCa) patients using a national database. We found that low-dose rate brachytherapy (LDR-B) boost, a method being used less frequently, was associated with better overall survival when compared to dose-escalated external-beam radiotherapy alone for men with unfavorable PCa. Randomized trials are needed to confirm that LDR-B boost is the ideal treatment.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Skyler B. Johnson, Nataniel H. Lester-Coll, Jacqueline R. Kelly, Benjamin H. Kann, James B. Yu, Sameer K. Nath,